Opening the book…
Regenerative medicine seeks to restore or replace damaged cells, tissues, or
functions. Approaches may use cells, tissue constructs, biological signals, or combinations of materials. Cell therapy administers cells for an intended therapeutic effect. Some cell therapies aim to repair tissue; others target a disease through immune activity or another function.
Autologous cells come from the person who will receive them. Allogeneic cells come from another individual. Autologous approaches require a separate source-to-recipient link for each patient. Allogeneic approaches can potentially support multiple recipients from a donor-derived supply, but require attention to donor source, recipient interactions, and consistency. Neither term alone establishes safety or effectiveness.
Figure 16.2. Autologous and allogeneic describe the relationship between the cell source and recipient. The diagram shows that relationship only; it does not imply a particular manufacturing process or immune response. Original diagram.
An established example that uses cultured cells is MACI, a product containing a patient's cultured chondrocytes on a porcine collagen membrane. FDA lists it for repair of specified full-thickness knee cartilage defects in adults. The example links tissue collection, cell expansion, a supporting membrane, and a defined clinical application. It does not establish that any cultured cell population can repair cartilage or that the product treats every joint disorder.
Another important application is chimeric antigen receptor T-cell therapy, or CAR T-cell therapy. T cells are modified to express a receptor that helps them recognize a selected target. Some approved products use a patient's own cells for specified blood cancers. KYMRIAH is one example of an approved, genetically modified autologous T-cell product with defined indications.
CAR T-cell treatment shows why function and safety must be assessed together. Activated immune cells can attack target cells, while the treatment can also cause serious adverse effects, including cytokine release syndrome and neurologic problems. Clinical monitoring and management are therefore part of the treatment program.
These applications share laboratory skills with basic cell culture: aseptic handling, cell counting, characterization, and documentation. Their success depends on integrating those skills into a product-specific development and quality system. A classroom or research culture is not converted into a clinical product simply by increasing its cell number.
Attribution: Images AI-generated using ChatGPT Modified by Emalee Mackenzie, Irvine Valley College. Licensed under CC BY-NC-SA
This page titled 16.9: Cell Therapies and Regenerative Medicine was last modified on Wed, 21 Oct 2026 01:35:46 GMT and is shared under a CC BY-NC-SA 4.0 license and was authored, remixed, and/or curated by Emalee MacKenzie.
The book could not be loaded just now.